Global Fiducial Markers Market Size study & Forecast, by Product (Metal Based Markers, Polymer Based Markers, Other Fiducial Markers) by Modality (CT/CBCT, MRI, Radiotherapy, Ultrasound), by Cancer type (Lung Cancer, Breast Cancer, Gastric Cancer, Prostat

Global Fiducial Markers Market Size study & Forecast, by Product (Metal Based Markers, Polymer Based Markers, Other Fiducial Markers) by Modality (CT/CBCT, MRI, Radiotherapy, Ultrasound), by Cancer type (Lung Cancer, Breast Cancer, Gastric Cancer, Prostate Cancer, Other Cancers), by End User (Hospitals and Outpatient Facilities, Cancer Research Centers, Independent Radiotherapy Centers) and Regional Analysis, 2023-2030

Global Fiducial Markers Market is valued approximately at USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. A fiducial marker is a tool used in radiotherapy treatments to identify where surgery was performed and delivered precise radiation dose. The fiducial marker can pinpoint the exact location of the tumor and let the doctor give the patient the right amount of radiation without damaging surrounding tissue. Fiducial markers come in a variety of forms, including metal- and polymer-based markers, among others. The fiducial marker technology may also offer a 3D image of the fiducials and produce a report with a precise diagnosis and suggested treatment actions. Major factors that are expected to boost the growth of the Fiducial Markers market in the forecast period are the rise in the prevalence of cancer and the cohesive reimbursement policies. Furthermore, the increase in awareness on the radiotherapy is further propelling the growth of the Fiducial Markers market.

Moreover, the increase in cancer prevalence contributes to the growth of the Fiducial Markers Market. Fiducial markers are used in radiation therapy to precisely target and deliver radiation to cancerous tumors. As the prevalence of cancer increases, the demand for radiation therapy also rises, driving the need for fiducial markers. According to Cancer Tomorrow, in 2020, the number of cancer cases in China was around 4.57 million and the number is anticipated to reach 5.81 million by 2030. As a result, rising number of cancer cases is anticipated to create the lucrative opportunity for the market growth. Additionally, upsurge in the investments and spending for the cancer research is anticipated to create the lucrative opportunity for the market during forecast period. However, the high cost of Fiducial Markers stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Fiducial Markers Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, streamlined reimbursement rules, and public health initiatives. Additionally, the increasing use of advanced radiation techniques and imaging modalities will increase product demand in the area, boosting market expansion. Asia Pacific is expected to grow at fastest growth rate during the forecast period, owing to highly unmet clinical needs together with a rise of cancer care initiatives, particularly in China and India, are expected to boost the region’s growth.

Major market player included in this report are:
CIVCO Radiotherapy
IZI Medical Products
Naslund Medical AB
Medtronic PLC
QlRad, Inc.
QFIX
Boston Scientific Corp.
Nanovi A/S
Eckert & Ziegler
IBA Dosimetry GmbH

Recent Developments in the Market:
In March 2020, the liquid fiducial marker from Nanovi A/BioXmark S has achieved CE approval. Over the anticipated time, these changes are projected to increase the market in Germany.

Global Fiducial Markers Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Modality, Cancer type, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Metal Based Markers
Polymer Based Markers
Other Fiducial Markers
By Modality:
CT/CBCT
MRI
Radiotherapy
Ultrasound
By Cancer type:
Lung Cancer
Breast Cancer
Gastric Cancer
Prostate Cancer
Other Cancers
By End User:
Hospitals and Outpatient Facilities
Cancer Research Centers
Independent Radiotherapy Centers
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
CIVCO Radiotherapy
IZI Medical Products
Naslund Medical AB
Medtronic PLC
QlRad, Inc.
QFIX
Boston Scientific Corp.
Nanovi A/S
Eckert & Ziegler
IBA Dosimetry GmbH

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.